Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>APOE</i> Genotype Modifies the Predictive Performance of Plasma Biomarkers for Amyloid Plaque Burden in Subjective Cognitive Decline.

Journal of Korean medical science·2026
Same author

Nano formulation of Sophora japonica extract stimulates osteogenic activity in osteoblasts.

Journal of food science and technology·2026
Same author

Mixing-sequence-governed dispersion and processability of electrode slurries with carboxymethyl cellulose and cellulose nanofibrils.

Carbohydrate polymers·2026
Same author

A clinically feasible framework to estimate tau pathology and clinical-biological discordance in the Alzheimer's disease spectrum.

Alzheimer's research & therapy·2026
Same author

Prediction of cognitive impairment through speech data analysis: A comparative evaluation of deep learning models.

PloS one·2026
Same author

Reversibility of cognitive and psychiatric impairments following surgical resection of frontotemporal meningiomas: a predictive factor analysis.

BMC neurology·2026

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Fred Kim1, Tianyang Xi1, Han Joo Lee2

  • 1AriBio Co., Ltd., San Diego, CA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

AR1001 (mirodenafil) shows promise as an Alzheimer's disease (AD) monotherapy. In a phase 2 trial, 30 mg AR1001 significantly improved cognition and reduced AD biomarkers in patients not taking other AD medications.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biomarkers

Background:

  • AR1001 (mirodenafil) is an investigational oral phosphodiesterase 5 (PDE5) inhibitor for Alzheimer's disease (AD).
  • A phase 2 trial evaluated AR1001's safety and efficacy in mild to moderate AD patients.
  • AR1001 demonstrated acceptable safety at 10 mg and 30 mg doses over 26 weeks.

Purpose of the Study:

  • To assess the safety and efficacy of AR1001 in patients with mild to moderate AD.
  • To evaluate AR1001's impact on cognitive function and AD biomarkers.
  • To explore AR1001's potential as a monotherapy for AD.

Main Methods:

  • A double-blind, randomized, placebo-controlled trial involving 210 mild to moderate AD patients.
  • Participants received daily oral doses of placebo, 10 mg AR1001, or 30 mg AR1001 for 26 weeks.
  • Subgroup analyses examined effects based on concomitant AD medication use, focusing on ADAS-Cog-13 and plasma biomarkers (ptau-181, ptau-217).

Main Results:

  • While the primary endpoint (ADAS-Cog-13) did not show significant differences overall, the 30 mg AR1001 group showed reduced plasma ptau-181 and ptau-217 compared to placebo.
  • In participants not on concomitant AD medication, 30 mg AR1001 monotherapy showed a statistically significant improvement on ADAS-Cog-13 (p=0.012).
  • AR1001 30 mg monotherapy also led to significant reductions in plasma ptau-181 (p=0.023) and ptau-217 (p<0.05) compared to placebo.

Conclusions:

  • AR1001 (mirodenafil) at 30 mg demonstrated potential as a monotherapy for Alzheimer's disease.
  • Subgroup analysis indicated that patients treated with AR1001 30 mg without other AD medications experienced cognitive benefits.
  • The study highlights AR1001's potential to modify AD progression by reducing key pathological biomarkers.